Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE-HF2 trial and comparison to COAPT and MITRA-FR trials.
Stefan D AnkerTim FriedeRalph Stephan von BardelebenJaved ButlerMuhammad Shahzeb KhanMonika DiekJutta HeinrichMartin GeyerMarius PlaczekRoberto FerrariWilliam T AbrahamOttavio AlfieriAngelo AuricchioAntoni Bayes-GenisJohn G F ClelandGerasimos FilippatosFinn GustafssonWilhelm HaverkampMalte KelmKarl-Heinz KuckUlf LandmesserAldo P MaggioniMarco MetraVlasis NiniosMark C PetrieTienush RassafFrank RuschitzkaUlrich SchäferP Christian SchulzeKonstantinos SpargiasAlec VahanianJose Luis ZamoranoAndreas ZeiherMahir KarakasFriedrich KoehlerMitja LainscakAlper ÖnerNikolaos MezilisEfstratios K TheofilogiannakosIlias NiniosMichael ChrissoherisPanagiota KourkoveliKonstantinos PapadopoulosGrzegorz SmolkaWojciech WojakowskiKrzysztof ReczuchFausto J PintoKrzysztof ZmudkaZbigniew KalarusMarianna AdamoEvelyn Santiago-VacasTobias Friedrich RufMichael GrossJoern TongersGerd HasenfußWolfgang SchillingerPiotr PonikowskiPublished in: European journal of heart failure (2024)
Patients enrolled in RESHAPE-HF2 represent a third distinct population where MitraClip was tested in, that is one mainly comprising of patients with moderate-to-severe FMR instead of only severe FMR, as enrolled in the COAPT and MITRA-FR trials. The results of RESHAPE-HF2 will provide crucial insights regarding broader application of the transcatheter edge-to-edge repair procedure in clinical practice.